Replies to post #215 on Fate Therapeutics Inc (FATE)

[jondoeuk]

When a DR5 specific TRAIL variant is expressed on NK cells, it significantly enhances their cytotoxicity based on preclinical data.

We now have clinical data from two mAbs https://www.globenewswire.com/news-release/2023/06/02/2681484/0/en/IGM-Biosciences-Announces-Update-on-IGM-8444-Phase-1-Trial-and-Future-Clinical-Development.html

We always need new & better to potentially best-in-class drugs with novel mechanisms of action. Presenting a new- DR5 drug for patients with #chondrosarcoma @ASCO#ASCO23 @CCR_AACR @AACR
-->Started working with 1st gen DR5 targeting Rx in 2012
--> FINALLY we have a 3rd… pic.twitter.com/ksTOFdMkVr

— Vivek Subbiah, MD (@VivekSubbiah) June 11, 2023